Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine · 19.02.2026 · 394 (8) · 739-752
DOI: 10.1056/nejmoa2514663 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 19.02.2026. Verfasst von Luciano J Costa und 44 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma. Die Arbeit wurde bisher 118-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Johnson & Johnson.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham.
- Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.
- Universite de Toulouse, Centre Hospitalier Universitaire, Service d'Hematologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Cancer Research Center of Toulouse, Toulouse, France.
- Emory University, Winship Cancer Institute, Atlanta.
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing.
- Royal Marsden NHS Foundation Trust, London.
ORCID-Profile: Luciano J Costa, Aurore Perrot
Förderung
- NCI NIH HHS
- Johnson & Johnson
Zitieren
APA
Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., Reece, D., Niu, T., Mylin, A. K., Hansen, C. T., Teipel, R., Besemer, B., Dimopoulos, M. A., Zamagni, E., Yoshihara, S., …, & MajesTEC-3 Trial Investigators (2026). Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 394(8), 739-752. https://doi.org/10.1056/nejmoa2514663
Vancouver
Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, et al. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 2026;394(8):739-752. doi:10.1056/nejmoa2514663
BibTeX
@article{Costa2026,
author = {Costa, Luciano J and Bahlis, Nizar J and Perrot, Aurore and Nooka, Ajay K and Lu, Jin and Pawlyn, Charlotte and Mina, Roberto and Caeiro, Gaston and Kentos, Alain and Hungria, Vania and Reece, Donna and Niu, Ting and Mylin, Anne K and Hansen, Charlotte T and Teipel, Raphael and Besemer, Britta and Dimopoulos, Meletios A and Zamagni, Elena and Yoshihara, Satoshi and Kim, Kihyun and Min, Chang Ki and Geerts, Paul and Van Leeuwen-Segarceanu, Elena and Tyczynska, Agata and Reguera, Juan Luis and Johansson, Magnus and Hansson, Markus and Turgut, Mehmet and Grey, Mark and Sidana, Surbhi and Rodriguez-Otero, Paula and Martinez-Lopez, Joaquin and Hashmi, Hamza and Carson, Robin and Kobos, Rachel and Sun, Weili and Lantz, Kristen and Seifert, Anne and Briseno-Toomey, Deborah and O'Rourke, Lisa and Rubin, Maria and Vieyra, Diego and Kang, Lijuan and Mateos, Maria Victoria and MajesTEC-3 Trial Investigators, MajesTEC-3 Trial Investigators},
title = {Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {8},
pages = {739--752},
doi = {10.1056/nejmoa2514663}
}
EUVIMED